Diverse long-time progression-free survival (PFS) and overall survival (OS), based on metastasis location, in metastatic urothelial carcinoma (MUC) patients treated with pemetexed (P) in monotherapy: Results from a longer follow-up of Arco del Mediterraneo Group. | Publicación